1. Home
  2. ENV vs CINGW Comparison

ENV vs CINGW Comparison

Compare ENV & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENV
  • CINGW
  • Stock Information
  • Founded
  • ENV 1999
  • CINGW N/A
  • Country
  • ENV United States
  • CINGW United States
  • Employees
  • ENV N/A
  • CINGW 13
  • Industry
  • ENV Business Services
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENV Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • ENV Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • ENV N/A
  • CINGW N/A
  • IPO Year
  • ENV 2010
  • CINGW 2021
  • Fundamental
  • Price
  • ENV $63.11
  • CINGW $0.04
  • Analyst Decision
  • ENV Hold
  • CINGW
  • Analyst Count
  • ENV 8
  • CINGW 0
  • Target Price
  • ENV $61.88
  • CINGW N/A
  • AVG Volume (30 Days)
  • ENV 946.8K
  • CINGW N/A
  • Earning Date
  • ENV 11-07-2024
  • CINGW N/A
  • Dividend Yield
  • ENV N/A
  • CINGW N/A
  • EPS Growth
  • ENV N/A
  • CINGW N/A
  • EPS
  • ENV N/A
  • CINGW N/A
  • Revenue
  • ENV $1,336,804,000.00
  • CINGW N/A
  • Revenue This Year
  • ENV $11.83
  • CINGW N/A
  • Revenue Next Year
  • ENV $10.19
  • CINGW N/A
  • P/E Ratio
  • ENV N/A
  • CINGW N/A
  • Revenue Growth
  • ENV 9.50
  • CINGW N/A
  • 52 Week Low
  • ENV $36.43
  • CINGW N/A
  • 52 Week High
  • ENV $73.04
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • ENV 68.64
  • CINGW N/A
  • Support Level
  • ENV $62.90
  • CINGW N/A
  • Resistance Level
  • ENV $63.09
  • CINGW N/A
  • Average True Range (ATR)
  • ENV 0.13
  • CINGW 0.00
  • MACD
  • ENV 0.02
  • CINGW 0.00
  • Stochastic Oscillator
  • ENV 62.26
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: